Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers. Clasp is developing T cell engagers to match both the specific characteristics of the patient’s immune system and the specific genetics of their tumor, enabling the creation of exquisitely personalized, yet off-the-shelf, therapeutics. Built upon academic research in the labs of Bert Vogelstein and Drew Pardoll at Johns Hopkins University, Clasp is backed by prominent life sciences investors including Catalio Capital Management, Third Rock Ventures and Novo Holdings. The company was launched in March 2024 and is based in Cambridge, MA and Rockville, MD. For more information about Clasp, please visit www.clasptx.com
Company Details
- Employees
- 50
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.clasptx.com
Clasp Therapeutics Questions
Clasp Therapeutics's website is http://www.clasptx.com
Clasp Therapeutics's LinkedIn profile is https://www.linkedin.com/company/clasp-therapeutics
Clasp Therapeutics has
50 employees.
View email and phone details for 50
employees at Clasp Therapeutics.
Clasp Therapeutics's industry is
Biotechnology Research
Clasp Therapeutics's top competitors are
Apogee Therapeutics,
Avenzo Therapeutics,
Sionna Therapeutics,
Beam Therapeutics,
Mirador Therapeutics,
Seaport Therapeutics,
Capstan Therapeutics,
Engrail Therapeutics,
Diagonal Therapeutics,
Alumis.
Clasp Therapeutics's categories are Biotechnology Research
Clasp Therapeutics's founding year is 2020
